Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma
Yıl: 2022 Cilt: 8 Sayı: 4 Sayfa Aralığı: 695 - 702 Metin Dili: İngilizce DOI: 10.28979/jarnas.1129991 İndeks Tarihi: 22-12-2022
Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma
Öz: Colchicine (COL) reduces the frequency of attacks in Familial Mediterranean Fever (FMF) patients and is effective in preventing and arresting renal amyloidosis in most patients. COL has a narrow therapeutic window. The blood concentration to achieve therapeutic effects can be determined by Therapeutic Drug Monitoring (TDM). However, the use of selective and sensitive analytical methods is necessary for achieving success with TDM. The purpose of this study is to develop and validate a new method for quantitative assay of COL in human plasma samples by liquid chromatograph- tandem mass spectrometry (LC-MS/MS). In our study, to 1ml plasma sample, 0.25 ml internal standard solution was added. The solution was extracted by liquid-liquid extraction (LLE). The method was validated according to the European Medicines Agency (EMEA). The total run time was 8 min in LC-MS/MS. The method has been validated over the 0.25 - 8.0 ng/mL calibration range for COL. It was seen that the method has been validated since the results of the analysis meet the EMEA criteria. In our study, COL plasma levels were found to be approximately 1.097±0.42 ng/ml in 40 FMF patients using an oral dose of 1.5-2 mg/day. A validated, rapid, simple, cost-effective, and sensitive LC-MS/MS method was developed and optimized for quantitation of COL in plasma. It has been thought that pharmacokinetic studies of COL in plasma can be performed easily using this validated method
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Angelidis, C., Kotsialou, Z., Kossyvakis, C., Vrettou, A. R., Zacharoulis, A., Kolokathis, F., Vasilios, K., & Giannopoulos, G. (2018). Colchicine pharmacokinetics and mechanism of action. Current pharmaceutical design, 24(6), 659-663. doi: https://doi.org/10.2174/1381612824666180123110042
- Bourgogne, E., Soichot, M., Latour, C., & Laprévote, O. (2013). Rugged and accurate quantitation of colchicine in human plasma to support colchicine poisoning monitoring by using turbulent-flow LC– MS/MS analysis. Bioanalysis, 5(23), 2889-2896. doi: https://doi.org/10.4155/bio.13.258
- Canbolat, F., Ozen, G., Ozilhan, S., Gulturk, S., Ozcetin, A., Unal A.U., Inanc, N., Atagunduz, P., Direskeneli, H., & Ozden, T. (2015a). Relationship Between Colchine Plasma Level and Frequency of Familial Mediterranean Fever Attacks. ACR/ARHP Annual Meeting, Abstract 941, USA. Retrived from: https://acrabstracts.org/abstract/relationship-between-colchine-plasma-level-and-frequency-of- familial-mediterranean-fever-attacks/
- Canbolat, F., Ozen, G., Ozilhan, S., Gulturk, S., Ozcetin, A., Unal, A. U., Inanc, N., Atagunduz, P., Direskeneli, H., & Ozden, T. (2015b). THU0549 Relationship Between Colchine Plasma Level and Frequency of Familial Mediterranean Fever Attacks.BMJ Journals Annals of The Rheumatic Diseases, 74 (2). Retrived from:https://ard.bmj.com/content/74/Suppl_2/399.2
- Cerquaglia, C., Diaco, M., Nucera, G., Regina, M. L., Montalto, M., & Manna, R. (2005). Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Current Drug Targets-Inflammation & Allergy, 4(1), 117-124. doi: https://doi.org/10.2174/1568010053622984
- Cocco, G., Chu, D. C., & Pandolfi, S. (2010). Colchicine in clinical medicine. A guide for internists. European journal of internal medicine, 21(6), 503-508. doi: https://doi.org/10.1016/j.ejim.2010.09.010
- Chèze, M., Deveaux, M., & Pèpin, G. (2006). Liquid chromatography-tandem mass spectrometry for the determination of colchicine in postmortem body fluids. Case report of two fatalities and review of the literature. Journal of analytical toxicology, 30(8), 593-598. doi: https://doi.org/10.1093/jat/30.8.593
- EMEA Committee for Medicinal Products for Human Use (2011). Guideline on bioanalytical method validation. European Medicines Agency EMEA. CHMP/EWP/192217/2009: 1-22 (cited 2011 August 01). Retrived from: www. ema. europa. eu/ema/pages/includes/document/open_document. jsp.
- Fabresse, N., Allard, J., Sardaby, M., Thompson, A., Clutton, R. E., Eddleston, M., & Alvarez, J. C. (2017). LC–MS/MS quantification of free and Fab-bound colchicine in plasma, urine and organs following colchicine administration and colchicine-specific Fab fragments treatment in Göttingen minipigs. Journal of Chromatography B, 1060, 400-406. doi:https://doi.org/10.1016/j.jchromb.2017.06.034
- Goldbart, A., Press, J., Sofer, S., & Kapelushnik, J. (2000). Near fatal acute colchicine intoxication in a child. A case report. European journal of pediatrics, 159(12), 895-897. doi:https://doi.org/10.1007/PL00008364
- Gowda, B. G. (2014). High-Performance liquid chromatographic determination of colchicine in pharmaceutical formulations and biological fluids. Int. J Pharm Pharm Sci, 6, 335-337. Retrived from:https://web.archive.org/web/20180413121507id_/http://ijppsjournal.com/Vol6Issue6/9624.pdf
- Jones, G. R., Singer, P. P., & Bannach, B. (2002). Application of LC-MS analysis to a colchicine fatality. Journal of analytical toxicology, 26(6), 365-369. doi: https://doi.org/10.1093/jat/26.6.365
- Lidar, M., Scherrmann, J. M., Shinar, Y., Chetrit, A., Niel, E., Gershoni-Baruch, R., Langevitz, P., & Livneh, A. (2004). Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. In Seminars in arthritis and rheumatism (Vol. 33, No. 4, pp. 273-282). WB Saunders. doi: https://doi.org/10.1053/S0049-0172(03)00137-9
- Niel, E., & Scherrmann, J. M. (2006). Colchicine today. Joint Bone Spine, 73(6), 672-678. doi: https://doi.org/10.1016/j.jbspin.2006.03.006
- Tateishi, T., Soucek, P., Caraco, Y., Guengerich, F. P., & Wood, A. J. (1997). Colchicine biotransformation by human liver microsomes: identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochemical pharmacology, 53(1), 111-116. doi:https://doi.org/10.1016/S0006- 2952(96)00693-4
- Tracqui, A., Kintz, P., Ludes, B., Rouge, C., Douibi, H., & Mangin, P. (1996). High-performance liquid chromatography coupled to ion spray mass spectrometry for the determination of colchicine at ppb levels in human biofluids. Journal of Chromatography B: Biomedical Sciences and Applications, 675(2), 235- 242. doi: https://doi.org/10.1016/0378-4347(95)00386-X
- Wason, S., DiGiacinto, J. L., & Davis, M. W. (2012). Effects of grapefruit and Seville orange juices on the pharmacokinetic properties of colchicine in healthy subjects. Clinical therapeutics, 34(10), 2161-2173. doi: https://doi.org/10.1016/j.clinthera.2012.08.007
| APA | CANBOLAT F (2022). Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. , 695 - 702. 10.28979/jarnas.1129991 |
| Chicago | CANBOLAT FADİME Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. (2022): 695 - 702. 10.28979/jarnas.1129991 |
| MLA | CANBOLAT FADİME Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. , 2022, ss.695 - 702. 10.28979/jarnas.1129991 |
| AMA | CANBOLAT F Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. . 2022; 695 - 702. 10.28979/jarnas.1129991 |
| Vancouver | CANBOLAT F Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. . 2022; 695 - 702. 10.28979/jarnas.1129991 |
| IEEE | CANBOLAT F "Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma." , ss.695 - 702, 2022. 10.28979/jarnas.1129991 |
| ISNAD | CANBOLAT, FADİME. "Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma". (2022), 695-702. https://doi.org/10.28979/jarnas.1129991 |
| APA | CANBOLAT F (2022). Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. Journal of advanced research in natural and applied sciences (Online), 8(4), 695 - 702. 10.28979/jarnas.1129991 |
| Chicago | CANBOLAT FADİME Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. Journal of advanced research in natural and applied sciences (Online) 8, no.4 (2022): 695 - 702. 10.28979/jarnas.1129991 |
| MLA | CANBOLAT FADİME Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. Journal of advanced research in natural and applied sciences (Online), vol.8, no.4, 2022, ss.695 - 702. 10.28979/jarnas.1129991 |
| AMA | CANBOLAT F Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. Journal of advanced research in natural and applied sciences (Online). 2022; 8(4): 695 - 702. 10.28979/jarnas.1129991 |
| Vancouver | CANBOLAT F Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma. Journal of advanced research in natural and applied sciences (Online). 2022; 8(4): 695 - 702. 10.28979/jarnas.1129991 |
| IEEE | CANBOLAT F "Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma." Journal of advanced research in natural and applied sciences (Online), 8, ss.695 - 702, 2022. 10.28979/jarnas.1129991 |
| ISNAD | CANBOLAT, FADİME. "Validation of Colchicine Assay Method for Therapeutic Drug Monitoring in Human Plasma". Journal of advanced research in natural and applied sciences (Online) 8/4 (2022), 695-702. https://doi.org/10.28979/jarnas.1129991 |
